Findings of MANIFEST-2 show “valuable evidence that the addition of pelabresib offers meaningful improvements over JAK inhibitor monotherapy as a first-line approach for patients with myelofibrosis,” ...
Jakafi led to improved symptom score and spleen volume reductions in patients with myelofibrosis, regardless of anemia or transfusion status, recent research showed. Patients with myelofibrosis who ...
Please provide your email address to receive an email when new articles are posted on . Individuals in the highest percentiles of spleen size may have an increased risk for developing hematologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results